6533b85cfe1ef96bd12bcb58

RESEARCH PRODUCT

Prevalence of older in-patients at risk of clopidogrel resistance according to the STIB score. Results from REPOSI registry

Anna GallottaMarengoni AlessandraLuca PasinaLaura CortesiNobili AlessandroReposi InvestigatorsMario BarbagalloLigia Juliana Dominguez Rodríguez

subject

Blood Plateletsmedicine.medical_specialtyTiclopidineSettore MED/09 - Medicina InternaHPRTreatment outcomeMEDLINEClopidogrel resistance030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicinePrevalenceInternal MedicinemedicineClopidogrel resistance HPR STIB score REPOSIHumansIn patientPlateletRegistriesSTIB score030212 general & internal medicineTiclopidineClopidogrel resistance; HPR; REPOSI; STIB score; Internal Medicinebusiness.industryClopidogrel resistanceREPOSISurgeryTreatment OutcomePlatelet aggregation inhibitorbusinessPlatelet Aggregation Inhibitorsmedicine.drug

description

The phenomenon of resistance to copidogrel catches the attention of a growing number of clinicians because of its frequency and the severity of adverse events related to it. The identification of patients with high platelet reactivity (HPR may help to improve their therapy applying the concept of personalized medicine, most important in the older people treated with polypharmacy. The existece of such a simple clinical method as the STIB score, that allows to predict the possible resistace to clopidogrel at the bedside without using expensive laboratory investigations, provides an attractive approach to the problem.

yearjournalcountryeditionlanguage
2017-01-01
10.1016/j.ejim.2017.03.024http://hdl.handle.net/10447/400035